Difference between revisions of "Team:ETH Zurich"

Line 132: Line 132:
  
 
<div id="second">
 
<div id="second">
−
<img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="Ec" width="300px" align="left">
+
<img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="Ec" width="500px" align="left">
 
</div>
 
</div>
  

Revision as of 13:59, 7 October 2017



Cancer kills over 8 million people every year. That's the entire population of Switzerland!

We need more specific therapies because current approaches result in many side-effects.
That's why we created CATE: Cancer-Targeting E. coli.

Learn more
CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors. We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites. Project description